A California-based dental products maker has added to its expanding intellectual property battle with a Danish rival over patents covering intraoral scanners and related equipment, filing two complaints Tuesday in Delaware federal court and one complaint Monday at the U.S. International Trade Commission.
Weighing in on venue rules in patent infringement disputes, nonprofit Washington Legal Foundation urged the full Federal Circuit on Monday to rehear arguments by Eli Lilly and Co. that a Cialis dispute resulting in a $20 million verdict against the pharma giant shouldn’t have been litigated in East Texas.
An accountant found guilty of helping a venture capitalist siphon $18 million from a fund through false tax returns has told a California federal court he should serve no time behind bars despite prosecutors' request for a "significant" prison sentence.
Investors suing ImmunoCellular Therapeutics Ltd. over an alleged illegal stock promotion scheme asked a California federal judge Monday to preliminarily approve a $1.1 million settlement nearly equal to the company's entire market capitalization.
A California federal judge overseeing allegations that Hoffmann La-Roche Inc.'s anti-malarial drug neurologically harmed a Navy veteran has sent the case back to state court, ruling there wasn't federal diversity jurisdiction because the company's principal place of business is in California, not New Jersey.
GNC knocked down a proposed securities class action accusing the retailer of misleading investors about nutrition supplements that contained unlawful ingredients after the Third Circuit found Tuesday that the plaintiffs have not sufficiently alleged that company executives were knowingly or recklessly deceptive.
The Third Circuit pressed the Federal Trade Commission on Tuesday to show why the court should revive the agency’s antitrust complaint alleging a Shire PLC unit delayed generic competition for a gastrointestinal infection drug through a series of sham regulatory petitions, expressing skepticism that a violation of federal law was “imminent.”
Endo International PLC and several of its executives must face an investor suit alleging the company knowingly misrepresented the safety of its Opana opioid, leading to a significant stock drop when the drug was forcibly removed from the market, after a Pennsylvania federal judge said Monday that the shareholders sufficiently pled their claims.
A medical device developer has settled a case accusing a California attorney of scamming it out of $1.76 million by misrepresenting her ability to connect the company with potential clients in Asia and continuously trying to get more money.
The head of Fish & Richardson PC’s life sciences litigation practice, Jonathan Singer, persuaded a federal judge to overturn a $2.5 billion patent infringement verdict against Gilead Sciences Inc., earning him a spot as one of Law360's 2018 Life Sciences MVPs.
Shire LLC will have to turn over documents in an antitrust suit accusing it and Actavis of settling a patent dispute over an ADHD drug on anti-competitive terms, a Massachusetts federal judge ruled Monday.
The U.S. Securities and Exchange Commission asked a New York federal judge on Friday to reject a Bronxville businessman’s dismissal bid that levies a “series of unfocused attacks” on the agency’s civil suit alleging that he manipulated a microcap company’s stock in an $11.5 million fraud scheme.
The Federal Circuit on Monday upheld a decision finding an inventory restocking technology patent invalid because it covers only an abstract idea, rejecting arguments the patent wasn’t eligible for the America Invents Act’s covered business method review program.
A Keryx Biopharmaceuticals Inc. investor sued Monday in Delaware Chancery Court for access to company records on a pending merger with Akebia Therapeutics Inc., saying the documents are needed to investigate potentially conflicted actions in the run-up to an approval vote Tuesday.
A New York University faculty member and a former U.S. Food and Drug Administration official have hit the agency with a suit challenging a rule they said relaxed the reporting requirements for researchers doing certain clinical trials.
A Pennsylvania federal judge largely refused Friday to toss antitrust claims from buyers of Johnson & Johnson immunosuppressant Remicade, concluding that only sham litigation allegations and some state law consumer protection accusations must go while maintaining most of the suit alleging J&J compelled insurers not to cover competing biosimilars.
Olympus Corp. and a former executive pled guilty in New Jersey federal court Monday to distributing medical scopes in the United States without disclosing known risks of infection, which will cost the company $85 million in fines and forfeitures, the U.S. Department of Justice announced.
Federal prosecutors have abandoned insider trading and perjury charges against medical device executive James Mazzo after two juries deadlocked on whether he intended to tip longtime Orioles third baseman Doug DeCinces to merger plans.
A receiver appointed to help liquidate the assets of BioChemics Inc. as the government tries to collect on a nearly $18 million securities fraud judgment has tapped two law firms, Sunstein Kann Murphy & Timbers LLP and Nields Lemack & Frame LLC, to maintain the Massachusetts company's intellectual property.
A Delaware Chancery Court on Monday tossed a biotech firm’s suit seeking $100 million in losses and triple damages from the German-based parent of Fraunhofer USA Inc. for fraudulent use and theft of its intellectual property, finding that the firm correctly sued the German parent in chancery court but moved too late to protect its claims.
The recent settlement between Société Générale and U.S. regulators illustrates that U.S. sanctions enforcement authorities may be shifting their attention back to large financial institutions after several years of relatively quiet enforcement across the financial services industry, say attorneys with Ropes & Gray LLP.
In Helsinn v. Teva, the U.S. Supreme Court will resolve whether nonpublic sales or offers to sell still qualify as prior art under the post-America Invents Act on-sale bar. Ahead of Tuesday's oral argument, David Bassett and Christine Duh of WilmerHale examine the briefing from both sides.
Two new rules from the Centers for Medicare & Medicaid Services bring changes that collectively reflect movement toward promoting site neutrality and opening all telehealth services to Medicare reimbursement, say attorneys at Ropes & Gray LLP.
Plaintiffs in the Smith & Nephew Birmingham Hip Resurfacing multidistrict litigation were subject to different states' statutes of limitations. But whether you bleed Michigan blue or you live where a grizzly bear is your only neighbor, preemption unites us all, says Michelle Hart Yeary of Dechert LLP.
A recent advisory opinion from the Office of the Inspector General for the U.S. Department of Health and Human Services — responding to a proposal to provide hospitals with a free specialty drug — took a striking deviation from the traditional advisory opinion process, say Jeffrey Mittleman and Andrew Namkung of Holland & Knight LLP.
Permitting jurors to submit written questions, or even to pose questions orally to witnesses on the stand, advances several important goals and promotes both fairness and efficiency, says Matthew Wright of McCarter & English LLP.
Following the First Circuit's decision last month in the Asacol antitrust litigation, some predicted the end of the Rule 23 class action process. While there is much of interest in the opinion, early comments overstated the court’s concerns and views, says Fred Isquith of Wolf Haldenstein Adler Freeman & Herz LLP.
The California Supreme Court's recent decision in Sheppard Mullin v. J-M Manufacturing has cast doubt on arbitration clauses in attorney engagement agreements, jeopardizing the efficient resolution of malpractice claims and fee disputes, say Sharon Ben-Shahar Mayer and Mark Drooks of Bird Marella Boxer Wolpert Nessim Drooks Lincenberg & Rhow PC.
Attorneys at Albert Einstein College of Medicine, Perkins Coie LLP and the Healthcare Association of New York State reflect on lessons they learned the hard way when transitioning to in-house counsel positions.
In this edition of California Tax Takes, attorneys from Reed Smith LLP analyze special ballot initiatives like Proposition C in light of California's Constitution as recently examined in the California Cannabis Coalition v. City of Upland case.